Lynne Lederman, PhD

Articles

Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-Thalassemia

December 11th 2019

A majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).

Initial Higher-Dose Duvelisib Improves Responses in Relapsed/Refractory PTCL

December 9th 2019

Patients with relapsed/refractory peripheral T-cell lymphoma who received a higher initial dose of duvelisib at 75 mg BID had a higher overall response rate of 62% than those who received 25 mg BID.

Selinexor Triplet Highly Active in Relapsed Myeloma

September 16th 2019

The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.

Anti-BCMA BiTE AMG 701 Shows Preclinical Promise in Multiple Myeloma

September 16th 2019

AMG 701, a half-life–extended anti-BCMA bispecific T-cell engager, showed promising in vitro antimyeloma activity and characteristics suitable for once-weekly dosing in patients with multiple myeloma, according to findings presented at the 17th International Myeloma Workshop.

Melflufen Regimen Elicits Activity in Relapsed Myeloma With Extramedullary Disease

September 16th 2019

Melflufen and dexamethasone demonstrated encouraging activity in patients with relapsed/refractory multiple myeloma with and without extramedullary disease, with response rates higher than those observed in prior studies of other agents.

Daratumumab Plus VRd Shows Improved sCR in Transplant-Eligible, Newly Diagnosed Myeloma

September 15th 2019

The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone for transplant-eligible patients with newly diagnosed multiple myeloma improved the depth of response without affecting stem cell mobilization or hematopoietic reconstitution.

Iberdomide Shows Promise in Heavily Pretreated Multiple Myeloma

September 15th 2019

The novel agent iberdomide (formerly CC-220) was safe and showed antitumor activity when combined with dexamethasone in patients with heavily pretreated, relapsed/refractory multiple myeloma, according to findings from a phase Ib/IIa study presented at the 17th International Myeloma Workshop.

Isatuximab Quadruplet Active in High-Risk, Newly Diagnosed Myeloma

September 14th 2019

A quadruplet regimen combining the anti-CD38 monoclonal antibody isatuximab with carfilzomib, lenalidomide, and dexamethasone was safe and had a 100% response rate among 10 patients enrolled in the safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.

Findings Clarify Picture for HER2-Positive Breast Cancer

May 1st 2018

A panel of experts discuss the latest developments in the treatment of patients with HER2-positive breast cancer.

Encouraging Activity Seen With Glembatumumab Vedotin in Advanced Melanoma

July 14th 2017

The antibody-drug conjugate glembatumumab vedotin demonstrated an 11% overall response rate in patients with refractory advanced melanoma who had received prior treatment with a checkpoint inhibitor and duration of response.

Lurbinectedin Shows Promise in Endometrial Cancer

June 18th 2017

Lurbinectedin (PM01183) induced a high rate of response as monotherapy and with doxorubicin or paclitaxel in patients with advanced endometrial cancer.

Mirvetuximab Soravtansine Shows Promise in Ovarian Cancer

June 12th 2017

Data from phase I pooled expansion cohorts showed that mirvetuximab soravtansine (IMGN853) induced a solid response rate in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.

Early Results Show Niraparib/Bevacizumab Combo Is Safe in Relapsed Ovarian Cancer

August 19th 2016

Results of a phase I trial demonstrate that the combination of niraparib and bevacizumab (Avastin) can be safely administered to patients with platinum-sensitive relapsed ovarian cancer.

"Stemness" Inhibitor Demonstrates Activity in Patients With Advanced Ovarian Cancer

August 12th 2016

Results of an early phase trial show that, for heavily pretreated patients with platinum-resistant ovarian cancer, a first-in-class cancer "stemness" inhibitor that targets the STAT3 pathway was found to demonstrate antitumor activity—and was also found to be well tolerated when combined with paclitaxel.

Avelumab Shows Promise in Early Trial for Advanced Ovarian Cancer

July 19th 2016

Avelumab, a fully human anti–PD-L1 IgG1 antibody, showed activity in patients with heavily pretreated recurrent or refractory ovarian cancer with an acceptable toxicity profile.

T-VEC/Pembrolizumab Combo Shows Early Promise in Advanced Melanoma

June 10th 2016

The combination of the oncolytic virus talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda) demonstrated evidence of clinical benefit, as well as an acceptable safety profile, in patients with advanced melanoma.

Process Unclear on How to Identify Mutations in Non-Lynch Syndrome Patients With CRC

June 9th 2016

Results of an analysis presented at the 2016 ASCO Annual Meeting demonstrate the difficulty in determining the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer (CRC) who do not harbor Lynch syndrome.

CancerLinQ Proof-of-Principle Prototype

October 21st 2013

This "learning health system" prototype was first unveiled on March 27 at an ASCO-hosted panel discussion on big data in cancer care at the National Press Club in Washington, DC.

AACR President Frank McCormick, PhD, Reflects on Past Progress and Looks to the Future

May 6th 2013

An interesting conversation with this year's AACR president, Frank McCormick, PhD, on the next big area of interest in cancer research, and what the future holds for cancer research progress.

Can Practices Successfully Dispense Oral Anticancer Agents In-House?

November 16th 2012

In-house dispensing of oral agents in the community oncology setting may provide a safer and more reliable and convenient way for patients to receive their medications.